NV-BELKIN
8.1.2024 02:01:33 CET | Business Wire | Press release
Belkin, a leading consumer electronics brand for 40 years, today introduced four new products across its mobile power and connectivity portfolios, underscoring Belkin innovation, design excellence, dedication to quality, and commitment to building products more responsibly. Belkin is showcasing its newly announced products at CES Unveiled Las Vegas – the official media event of CES 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240107725407/en/
Belkin supercharges into CES 2024 with powerful new product lineup (Photo: Business Wire)
Charging in a snap with Qi2
BoostCharge Pro 3-in-1 Magnetic Stand
Leveraging the new Qi2 standard, this powerful 3-in-1 wireless charger offers perfect alignment and reliable charging for Qi2-enabled devices at 15W, fast charging for Apple Watch Series 7 and later, and optimal charging for wireless earbuds. Built to include an adjustable hinge, users can effortlessly adjust the angle of the phone for optimal viewing while watching videos, reading articles or video chatting. It is made with a minimum 75% post-consumer recycled (PCR) materials.
$149.99 USD
Coming March 2024 to select markets worldwide
BoostCharge Pro Magnetic Power Bank
The Qi2 magnetic power bank delivers up to 15W of power for Qi2-enabled devices on-the-go, without the hassle of cables. It is engineered with an integrated kickstand for propping the phone up while streaming, reading, or chatting, and works with magnetic and MagSafe cases up to 3mm thick. “Power pass-through” allows for charging the power bank and Qi2 device in one simple action via USB-C port. Offered in 5K, 8K and 10K options, consumers can choose the best power bank for their charging needs. Internal housing (excluding cable) of this product is made with a minimum 72% PCR materials.
$59.99, $79.99, $99.99 USD
Coming March 2024 to select markets worldwide
Power-packed and compact with GaN
BoostCharge Pro 4-Port USB-C GaN Charger 200W
The new 4-Port USB-C GaN Wall Charger packs an impressive 200W of power for fast charging up to 4 devices at the same time. It supports high powered laptops and gaming laptops and is engineered with GaN technology and Programmable Power Supply (PPS) to provide efficient power output and smart power allocation, giving connected devices a safe and optimal charge. The 4-Port USB-C GaN Wall Charger declutters the workspace while charging laptops, tablets, phones, smart watches and earbuds simultaneously – no extra power bricks needed. It is compact and power-packed, measured at 92mm x 118.5mm x 35.5mm, and 650g/1.32lbs. The housing (excluding power cord) of this product is made with a minimum 72% PCR materials.
$129.99 USD
Coming March 2024 to belkin.com and select markets worldwide
6-in-1 Core GaN Dock
Belkin is innovating its docks category with the use of GaN to deliver smaller, more efficient, more responsible workspace solutions. Approximately 50 percent smaller1 than other 6-in-1 solutions and highly spec'd to support all essential needs, the Core GaN Dock features 1x HDMI port for high-definition display resolutions up to 4K, 2x USB-A ports for legacy devices, 2x USB-C ports (1 with 96W power delivery), and 1 gigabit ethernet port for secure and reliable Internet connection.
$139.99 USD
Available to order now on belkin.com
Coming soon to select retailers worldwide
Built more responsibly
In line with the company’s commitment to find more responsible ways to build products, Belkin’s newly announced BoostCharge solutions are made with a minimum of 72% PCR materials and sold in plastic-free packaging. One year since Belkin announced its transition to PCR, it has transitioned over 200 products to incorporate PCR, and has replaced 64 metric tons of virgin plastic with PCR materials. Belkin remains committed to its goal of 100% carbon neutrality in its offices and operations (scope 1 & 2 emissions) by 2025 while tackling product level emissions (scope 3).
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From the humble beginnings of a garage in 1980s Southern California to a diverse, global technology company today, we remain forever inspired by the planet we live on, and the connection between people and technology.
1 Based on internal tests against competing non-GaN solutions with power supply unit. Dimensions: 80 x 80 x 48mm; surface area: 6,400mm
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240107725407/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom